Vividion Therapeutics is launching with $50 million pledged from investment firms Arch Venture Partners and Versant Ventures. Former Celgene president of research and early development Tom Daniel—who, as Xconomy reported previously, left the company over the summer to begin advising biotechs and venture firms—is executive chairman.